查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018937

神經復健設備市場：2026-2032年全球市場預測（按設備類型、技術、年齡層、應用程式和最終用戶分類）

Neurorehabilitation Devices Market by Device Type, Technology, Age Group, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，神經復健設備市場價值將達到 15.3 億美元，到 2026 年將成長到 16.6 億美元，到 2032 年將達到 26.2 億美元，複合年成長率為 7.98%。

主要市場統計數據
基準年 2025 15.3億美元
預計年份：2026年 16.6億美元
預測年份 2032 26.2億美元
複合年成長率 (%) 7.98%

全面概述當代臨床挑戰、相關人員的期望以及技術主導的神經復健設備引入和交付方式的重塑路徑。

神經復健設備正處於臨床需求與快速技術進步的交匯點，其發展動力源於神經系統疾病患者對功能恢復、減輕殘疾和提高生活品質的需求。臨床醫生日益尋求能夠整合精準診斷、適應性治療和可衡量療效的解決方案，而保險公司和醫療服務提供者則追求透過提高功能獨立性和降低長期照護成本來體現其價值。因此，開發人員正優先考慮互通性、以使用者為中心的設計和實證實踐，以縮短從創新到臨床應用的流程。

技術融合、分散式護理模式和價值主導的證據要求如何推動神經復健設備開發和交付的模式轉移。

在神經復健領域，多項變革正在發生，重塑著治療方法的發展、報銷和實施方式。感測、驅動和機器學習技術的進步使得設備能夠提供適應性治療方案，近乎即時地回應患者的復健進展。同時，機器人技術、神經調控、腦機介面和身臨其境型虛擬環境的融合，正在突破傳統框架，拓展治療的可能性，實現針對運動、認知和感覺功能恢復的多模態介入。

2025 年關稅調整對神經復健設備相關人員的供應鏈、籌資策略和區域製造考量的影響。

2025年推出的關稅政策和貿易措施為依賴跨境供應鏈採購零件和成品的製造商、供應商和醫療保健系統帶來了新的營運和策略考量。對於進口專用電子產品、感測器和驅動系統的公司而言，關稅帶來的額外成本促使它們重新評估籌資策略、供應商多元化和近岸外包方案。因此，採購團隊和營運經理現在更加關注進貨成本分析、總擁有成本和庫存彈性，以降低潛在的價格波動和供應中斷風險。

一個實用的細分框架，將醫療設備原型、臨床適應症、臨床環境、底層技術和病患年齡層連結起來，以幫助進行產品和臨床試驗設計。

有效的細分對於了解哪些領域的創新將產生最大的臨床和商業性影響至關重要，而對設備類型、應用、最終用戶、技術和年齡層進行詳細分析，可以揭示清晰的部署路徑。根據設備類型，該領域包括生物回饋療法系統、外骨骼、功能性電刺激設備、神經調節器和虛擬實境系統。在生物回饋療法系統中，肌電生物回饋療法和壓力生物回饋療法之間存在差異；外骨骼分為下肢型和上肢型；功能性電刺激器分為植入式和表面型；神經調節器分為侵入式和非侵入式；虛擬實境系統涵蓋從身臨其境型到非身臨其境型的各種體驗。根據應用，臨床適應症包括腦性麻痹、多發性硬化症、巴金森氏症、脊髓損傷和中風。腦性麻痹的亞型包括共濟失調型、運動障礙型和痙攣型；多發性硬化症的病程分為進行型和復發緩解型；帕金森氏症通常被認為是晚期和早期；脊髓損傷分為完全性損傷和不完全性損傷；中風病例分為出血性和缺血性病因。根據最終用戶，部署地點多種多樣，包括診所、居家照護、醫院、復健中心和研究機構。診所分為全科診所和專科診所；居家照護分為輔助住宅和自我管理；醫院分為私立醫院和公立醫院；復健中心分為住院部和門診部；研究機構分為學術機構和私立機構。根據技術，關鍵基礎技術包括腦機介面、機器人、經顱直流電刺激、經顱磁刺激和虛擬實境。腦機介面進一步分為侵入式和非侵入式；機器人分為末端執行器系統和外骨骼系統；經顱直流電刺激分為陽極模式和陰極模式；經顱磁刺激技術有多種變體，包括dTMS和rTMS；虛擬實境技術則分為身臨其境型和非身臨其境型兩種形式。根據年齡分組，患者群體可分為成人、老年人和兒童。成人通常分為18至40歲、41至64歲及65歲以上三個年齡層；老年人通常分為65至74歲、75至84歲及85歲以上三個年齡層；兒童患者包括青少年、兒童及新生兒。

影響美洲、歐洲、中東和非洲以及亞太地區臨床引進、報銷方式和生產策略的區域因素。

區域趨勢影響臨床應用、報銷政策和供應鏈策略，三大主要區域各自呈現出獨特的機會和挑戰。在美洲，分散的醫療服務體系、先進的支付方機制和活躍的創業投資投資為技術先進的醫療設備的商業化提供了支持，但聯邦和私人保險公司之間不同的報銷機制要求提供個體化的衛生經濟學證據，並製定本地化的市場准入計劃。歐洲、中東和非洲地區的特點是管理體制多樣化、基礎設施各異，以及公立和私人醫療機構並存，因此靈活的分銷模式和夥伴關係策略至關重要。在該地區的部分地區，集中化的報銷機構可以在證據符合政策標準時加速產品推廣，而在其他地區，則需要開展本地試點計畫來驗證可行性。亞太地區的特點是都市區進程迅速、製造能力強大、報銷途徑不斷發展。此外，該地區對擴充性且經濟高效的解決方案有著很高的需求，這些解決方案能夠適應龐大的患者群體和多樣化的醫療基礎設施。

在整個神經復健設備生態系統中，競爭和能力要求塑造了領導地位、夥伴關係模式和附加價值服務差異化。

神經復健設備生態系統的競爭動態呈現出多元化的特點，既有成熟的醫療技術公司，也有高度專業化的小規模研發企業、大學衍生公司以及其他行業的參與企業。主要企業強調跨學科研發能力、完善的監管合規流程和廣泛的臨床證據項目，而小規模的創新者則往往專注於特定適應症、顛覆性技術以及透過策略合作來加速臨床檢驗。在這種競爭格局下，與學術機構、大規模醫療系統或零件供應商建立合作關係是加速產品改善週期和提升臨床可信度的關鍵機制。

領導者面臨的實際策略挑戰：協調臨床證據、模組化產品開發、供應鏈韌性和支付方合作以實現永續成長。

產業領導者應採取兼顧短期商業化和長期平台開發的策略。首先，優先針對具有高影響力的適應症和已建立成熟醫保體系的醫療機構，產生臨床證據，從而創建案例研究，促進支付方參與和臨床醫生支持。同時，投資於模組化產品架構和軟體驅動型服務，以實現迭代更新，從而無需徹底重新設計硬體即可擴展治療適應症和護理路徑。

採用透明、多方面的研究途徑，結合臨床訪談、技術文獻整合、監管審查和供應商環境分析，以獲得可靠的見解。

本研究途徑結合了多方面的資訊收集和專家訪談，為分析建構了嚴謹且可重複的基礎。第一階段包括對臨床醫生、採購經理和技術開發人員進行結構化訪談，以了解實際應用中的挑戰、臨床優先事項和推動技術普及的因素。第二階段利用同儕審查的臨床文獻、監管指導文件和公開的技術規格來檢驗設備的功能和臨床應用案例。此外，供應商環境分析和專利分析還提供了有關技術差異化和智慧財產權趨勢的見解。

本文提出了將技術融合、政策轉變和營運要求相結合的策略重點，以將神經復健領域的創新轉化為臨床成果。

總之，神經復健設備生態系統正從一系列獨立技術的集合演變為一個以持續護理、可驗證的療效和可擴展的交付為優先的綜合治療平台。機器人技術、神經調控技術、腦機介面和身臨其境型環境等技術的融合，在拓展治療選擇的同時，也提高了臨床檢驗和互通性的門檻。同時，政策變化、收費系統調整以及區域醫療保健差異正在重塑供應鏈、定價策略和商業化進程。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 神經復健設備市場：依設備類型分類

  • 生物回饋療法系統
    • 肌電生物回饋療法
    • 壓力生物回饋療法
  • 外骨骼
    • 下肢
    • 上肢
  • 功能性電刺激設備
    • 嵌入式
    • 表類型
  • 神經控制裝置
    • 侵入性
    • 非侵入性
  • 虛擬實境系統
    • 身臨其境型
    • 非身臨其境型

第9章 神經復健設備市場：依技術分類

  • 腦機介面
    • 侵入性
    • 非侵入性
  • 機器人技術
    • 末端執行器
    • 外骨骼
  • 經顱直流電刺激
    • 陽極
    • 陰極
  • 經顱磁刺激
    • dTMS
    • rTMS
  • 虛擬實境
    • 身臨其境型
    • 非身臨其境型

第10章：神經復健設備市場：依年齡層別分類

  • 成人版
    • 18-40歲
    • 41-64歲
    • 65歲或以上
  • 老年人
    • 65-74歲
    • 75-84歲
    • 85歲或以上
  • 兒童
    • 青春期
    • 兒童
    • 新生

第11章 神經復健設備市場：依應用領域分類

  • 腦性麻痹
    • 共濟失調型
    • 運動障礙
    • 痙攣
  • 多發性硬化症
    • 進行性
    • 復發緩解型
  • 帕金森氏症
    • 晚期
    • 初期
  • 脊髓損傷
    • 完全的
    • 未完成
  • 中風
    • 出血性
    • 缺血性

第12章 神經復健設備市場：依最終用戶分類

  • 診所
    • 整體的
    • 專業領域
  • 居家照護
    • 輔助住宅
    • 自我管理
  • 醫院
    • 私人的
    • 民眾
  • 復健中心
    • 住院病人
    • 門診
  • 研究機構
    • 學術機構
    • 私人的

第13章 神經復健設備市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 神經復健設備市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 神經復健設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國神經復健設備市場

第17章：中國神經復健設備市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • ANT Neuro BV
  • Bioness, Inc.
  • Bionik Laboratories Corp.
  • BioXtreme Robotics Rehabilitation
  • Boston Scientific Corporation
  • BTS Bioengineering SpA
  • Cyberdyne Inc.
  • Ekso Bionics Holdings, Inc.
  • Hasomed GmbH
  • Hocoma AG
  • Kinetic Muscles, Inc.
  • Kinova Inc.
  • Medtronic plc
  • MindMaze SA
  • Myomo, Inc.
  • NeuroStyle Pte Ltd
  • ReWalk Robotics Ltd.
  • Synertial Europe Ltd.
  • Tyromotion GmbH
  • Vibrant Ltd.
Product Code: MRR-710B1F0AC5A5

The Neurorehabilitation Devices Market was valued at USD 1.53 billion in 2025 and is projected to grow to USD 1.66 billion in 2026, with a CAGR of 7.98%, reaching USD 2.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.53 billion
Estimated Year [2026] USD 1.66 billion
Forecast Year [2032] USD 2.62 billion
CAGR (%) 7.98%

Comprehensive orientation to contemporary clinical pressures, stakeholder expectations, and technology-driven pathways reshaping neurorehabilitation device adoption and care delivery

Neurorehabilitation devices sit at the intersection of clinical need and rapid technological advancement, driven by the imperative to restore function, reduce disability, and improve quality of life for patients with neurological conditions. Clinicians increasingly demand solutions that integrate precise diagnostics, adaptive therapy delivery, and measurable outcomes, while payers and providers seek demonstrable value through improved functional independence and reduced long-term care costs. As a result, developers are prioritizing interoperability, user-centered design, and evidence generation to shorten the path from innovation to clinical adoption.

Across diverse care settings, from acute hospitals to outpatient rehabilitation centers and home-based care, the emphasis is shifting toward devices that enable continuity of care and remote monitoring. Consequently, regulatory strategy, clinical validation, and real-world performance data have become core determinants of commercial success. In light of these dynamics, stakeholders must reconcile long development cycles and complex reimbursement environments with a growing expectation for personalization and scalable clinical workflows.

How converging technologies, decentralized care models, and value-driven evidence requirements are catalyzing a paradigm shift in neurorehabilitation device development and delivery

The neurorehabilitation landscape is undergoing multiple transformative shifts that are rewriting how therapies are developed, reimbursed, and delivered. Advances in sensing, actuation, and machine learning have enabled devices to offer adaptive therapy regimens that respond to patient progress in near real time. Simultaneously, the convergence of robotics, neuromodulation, brain-computer interfaces, and immersive virtual environments is expanding therapeutic possibilities beyond traditional boundaries, enabling multi-modal interventions that target motor, cognitive, and sensory recovery.

At the same time, clinical practice patterns are evolving toward decentralized care models. This shift increases demand for lightweight, user-friendly devices that support home-based therapy and clinician-supervised remote sessions. Payers and health systems are responding to population aging and rising chronic neurological disease prevalence by prioritizing interventions that demonstrate long-term functional gains and reduced downstream costs. As a result, product development roadmaps emphasize reimbursement strategy, longitudinal outcome tracking, and evidence generation to validate sustained clinical impact. Ultimately, these combined forces are accelerating a transition from discrete devices to integrated care platforms that connect patients, clinicians, and data in continuous therapeutic ecosystems.

Implications of 2025 tariff adjustments on supply chains, procurement strategies, and regional manufacturing considerations for neurorehabilitation device stakeholders

Tariff policies and trade measures instituted in 2025 introduced new operational and strategic considerations for manufacturers, suppliers, and health systems that rely on cross-border supply chains for components and finished devices. For firms that import specialized electronics, sensors, and actuation systems, the added costs associated with tariffs have prompted reassessments of sourcing strategy, supplier diversification, and nearshoring options. In turn, procurement teams and operations leaders have increased focus on landed cost analysis, total cost of ownership, and inventory resilience to mitigate potential price volatility and supply disruptions.

These dynamics have also influenced product roadmaps and commercialization tactics. Companies with global distribution networks are evaluating pricing models and contractual terms to preserve competitiveness in key regions while protecting margins. Meanwhile, strategic partnerships and regional manufacturing investments have gained traction as a way to circumvent trade frictions and shorten lead times. For clinical and research institutions, procurement cycles may lengthen as organizations re-evaluate capital budgets and consumable supply commitments in light of new tariff-related cost pressures, which reinforces the need for transparent value propositions and robust health economic evidence.

Actionable segmentation framework linking device archetypes, clinical indications, care settings, enabling technologies, and patient age groups to inform product and trial design

Effective segmentation is critical to understanding where innovations will have the greatest clinical and commercial impact, and a nuanced view across device type, application, end user, technology, and age group reveals distinct adoption pathways. Based on device type, the landscape includes biofeedback systems, exoskeletons, functional electrical stimulation devices, neuromodulation devices, and virtual reality systems; within biofeedback systems, distinctions arise between EMG biofeedback and pressure biofeedback, while exoskeletons bifurcate into lower limb and upper limb configurations, functional electrical stimulation devices differentiate between implantable and surface approaches, neuromodulation devices are classified as invasive or noninvasive, and virtual reality systems range from immersive to nonimmersive experiences. Based on application, clinical indications encompass cerebral palsy, multiple sclerosis, Parkinson's disease, spinal cord injury, and stroke; cerebral palsy subtypes include ataxic, dyskinetic, and spastic presentations, multiple sclerosis courses separate into progressive and relapsing remitting forms, Parkinson's disease is commonly considered in advanced and early stages, spinal cord injury is categorized as complete or incomplete, and stroke cases are differentiated into hemorrhagic and ischemic etiologies. Based on end user, deployments vary across clinics, home care, hospitals, rehabilitation centers, and research institutes; clinics split into general and specialty practices, home care is distinguished between assisted living and self-managed contexts, hospitals differ by private and public status, rehabilitation centers operate as inpatient or outpatient facilities, and research institutes are either academic or private. Based on technology, key enablers include brain-computer interfaces, robotics, transcranial direct current stimulation, transcranial magnetic stimulation, and virtual reality; brain-computer interfaces further separate into invasive and noninvasive modalities, robotics divides into end effector and exoskeleton systems, transcranial direct current stimulation is categorized into anodal and cathodal modes, transcranial magnetic stimulation appears as dTMS and rTMS variants, and virtual reality technologies split into immersive and nonimmersive formats. Based on age group, patient segments span adult, geriatric, and pediatric populations; adults are commonly profiled across ages 18 to 40, 41 to 64, and 65 plus, geriatric cohorts are often delineated as 65 to 74, 75 to 84, and 85 plus, and pediatric patients encompass adolescent, childhood, and neonatal stages.

Taken together, these layered segmentation dimensions create multiple vectors for product development and clinical validation. For example, an immersive virtual reality system designed for early-stage Parkinson's disease in an outpatient rehabilitation center will follow a different clinical evidence and commercialization path than a surface functional electrical stimulation device intended for incomplete spinal cord injury rehabilitation in home-based care. Therefore, companies must align regulatory strategy, clinical study designs, and implementation workflows to the precise intersection of device type, therapeutic indication, care setting, enabling technology, and patient age group to maximize adoption and therapeutic relevance.

Regional considerations influencing clinical adoption, reimbursement approaches, and manufacturing strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape clinical adoption, reimbursement policy, and supply chain strategy, and three macro regions present distinct opportunities and constraints. In the Americas, decentralized healthcare delivery, advanced payer systems, and strong venture capital activity support commercialization of technologically sophisticated devices, but heterogeneity in reimbursement across federal and private payers requires tailored health economic evidence and localized market access plans. Europe, Middle East & Africa features diverse regulatory regimes, variable infrastructure, and a mix of public and private providers that necessitate flexible distribution models and partnership strategies; in parts of the region, centralized reimbursement authorities can accelerate uptake where evidence meets policy thresholds, whereas other areas demand localized pilots to demonstrate feasibility. The Asia-Pacific region exhibits rapid adoption in urban centers, strong manufacturing capabilities, and evolving reimbursement pathways; it also presents high demand for scalable, cost-effective solutions that can be adapted to large patient volumes and diverse care infrastructures.

Across these regions, stakeholders must consider differences in clinical practice patterns, caregiver availability, and digital health readiness. Consequently, go-to-market strategies that integrate region-specific clinical validation, reimbursement dossiers, and training programs will be better positioned to achieve sustainable adoption. Furthermore, strategic regional partnerships, investments in local regulatory expertise, and targeted value communication are essential to bridge clinical evidence with procurement decision-making across these varied geographies.

Competitive dynamics and capability imperatives shaping leadership positions, partnership models, and value-added service differentiation across the neurorehabilitation device ecosystem

Competitive dynamics in the neurorehabilitation device ecosystem are defined by a blend of established medtech firms, specialized boutique developers, academic spinouts, and cross-industry entrants. Leading companies emphasize multi-disciplinary R&D capabilities, robust regulatory pathways, and broad clinical evidence programs, while smaller innovators often focus on niche indications, disruptive technologies, and strategic collaborations to accelerate clinical validation. Across the competitive landscape, alliance formation-whether with academic centers, large health systems, or component suppliers-has become a core mechanism to accelerate product iteration and strengthen clinical credibility.

In addition, differentiated service models are emerging as a competitive lever. Firms that combine devices with software platforms for remote monitoring, analytics, and clinician support can offer higher perceived value to purchasers who prioritize longitudinal outcome measurement. Intellectual property around algorithms, sensor fusion, and therapeutic dosing also influences competitive positioning, as does the ability to demonstrate reproducible functional gains in heterogeneous patient populations. As a result, companies are increasingly investing in outcomes research, payer engagement, and scalable manufacturing to fortify commercial defensibility.

Practical strategic imperatives for leaders to align clinical evidence, modular product development, supply chain resilience, and payer engagement for sustainable growth

Industry leaders should adopt a dual-focus strategy that balances near-term commercialization with long-term platform development. First, prioritize clinical evidence generation targeted to high-impact indications and care settings where reimbursement pathways are mature, thereby creating reference cases that facilitate payer engagement and clinician advocacy. Concurrently, invest in modular product architectures and software-enabled services that can be iteratively updated, allowing companies to expand therapeutic indications and care pathways without full hardware redesigns.

Second, strengthen supply chain resilience through strategic supplier diversification, regional manufacturing investments, and flexible procurement contracts to reduce exposure to tariff-driven cost fluctuations and component shortages. Third, cultivate partnerships with health systems, rehabilitation networks, and academic centers to co-develop training curricula, remote monitoring workflows, and value dossiers that align clinical outcomes with procurement requirements. Finally, integrate robust post-market evidence capture and health economic modeling into commercial operations to translate clinical performance into payer-relevant value propositions, thereby accelerating coverage decisions and institutional procurement.

Transparent, multi-method research approach combining primary clinical interviews, technical literature synthesis, regulatory review, and supplier landscape analysis for robust insights

The research approach combines multi-source evidence gathering with expert consultation to build a rigorous, reproducible foundation for analysis. Primary research included structured interviews with clinicians, procurement leaders, and technology developers to capture real-world implementation challenges, clinical priorities, and adoption drivers. Secondary research drew on peer-reviewed clinical literature, regulatory guidance documents, and publicly available technical specifications to validate device capabilities and clinical use cases. In addition, supplier landscape mapping and patent analysis provided insight into technological differentiation and intellectual property trends.

Data synthesis involved triangulating qualitative insights with quantitative operational indicators such as clinical trial activity, regulatory approvals, and published health outcomes where available. Throughout the process, methodological rigor was maintained by applying standardized criteria for evidence weighting, transparency in assumptions, and iterative validation with domain experts. This approach ensures that conclusions reflect clinical realities, regulatory constraints, and commercial imperatives relevant to stakeholders across the development, deployment, and procurement lifecycle.

Synthesis of technological convergence, policy shifts, and operational imperatives informing strategic priorities for translating neurorehabilitation innovation into clinical impact

In conclusion, the neurorehabilitation device ecosystem is evolving from a collection of discrete technologies into integrated therapeutic platforms that prioritize continuity of care, demonstrable outcomes, and scalable delivery. Technological convergence across robotics, neuromodulation, brain-computer interfaces, and immersive environments is expanding therapeutic options while also raising the bar for clinical validation and interoperability. Meanwhile, policy shifts, tariff dynamics, and regional healthcare variances are reshaping supply chains, pricing strategies, and commercialization timelines.

As stakeholders navigate this complexity, success will hinge on aligning product design with specific clinical pathways, investing in evidence that resonates with payers and providers, and building resilient operational models that can adapt to geopolitical and regulatory changes. Those who combine rigorous clinical science with pragmatic commercialization strategies and cooperative partnerships will be best positioned to translate innovation into sustained patient benefit and organizational growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurorehabilitation Devices Market, by Device Type

  • 8.1. Biofeedback System
    • 8.1.1. EMG Biofeedback
    • 8.1.2. Pressure Biofeedback
  • 8.2. Exoskeleton
    • 8.2.1. Lower Limb
    • 8.2.2. Upper Limb
  • 8.3. Functional Electrical Stimulation Device
    • 8.3.1. Implantable
    • 8.3.2. Surface
  • 8.4. Neuromodulation Device
    • 8.4.1. Invasive
    • 8.4.2. Noninvasive
  • 8.5. Virtual Reality System
    • 8.5.1. Immersive
    • 8.5.2. Nonimmersive

9. Neurorehabilitation Devices Market, by Technology

  • 9.1. Brain Computer Interface
    • 9.1.1. Invasive
    • 9.1.2. Noninvasive
  • 9.2. Robotics
    • 9.2.1. End Effector
    • 9.2.2. Exoskeleton
  • 9.3. Transcranial Direct Current Stimulation
    • 9.3.1. Anodal
    • 9.3.2. Cathodal
  • 9.4. Transcranial Magnetic Stimulation
    • 9.4.1. dTMS
    • 9.4.2. rTMS
  • 9.5. Virtual Reality
    • 9.5.1. Immersive
    • 9.5.2. Nonimmersive

10. Neurorehabilitation Devices Market, by Age Group

  • 10.1. Adult
    • 10.1.1. 18 To 40
    • 10.1.2. 41 To 64
    • 10.1.3. 65 Plus
  • 10.2. Geriatric
    • 10.2.1. 65 To 74
    • 10.2.2. 75 To 84
    • 10.2.3. 85 Plus
  • 10.3. Pediatric
    • 10.3.1. Adolescent
    • 10.3.2. Childhood
    • 10.3.3. Neonatal

11. Neurorehabilitation Devices Market, by Application

  • 11.1. Cerebral Palsy
    • 11.1.1. Ataxic
    • 11.1.2. Dyskinetic
    • 11.1.3. Spastic
  • 11.2. Multiple Sclerosis
    • 11.2.1. Progressive
    • 11.2.2. Relapsing Remitting
  • 11.3. Parkinson's Disease
    • 11.3.1. Advanced Stage
    • 11.3.2. Early Stage
  • 11.4. Spinal Cord Injury
    • 11.4.1. Complete
    • 11.4.2. Incomplete
  • 11.5. Stroke
    • 11.5.1. Hemorrhagic
    • 11.5.2. Ischemic

12. Neurorehabilitation Devices Market, by End User

  • 12.1. Clinics
    • 12.1.1. General
    • 12.1.2. Specialty
  • 12.2. Home Care
    • 12.2.1. Assisted Living
    • 12.2.2. Self Managed
  • 12.3. Hospitals
    • 12.3.1. Private
    • 12.3.2. Public
  • 12.4. Rehabilitation Centers
    • 12.4.1. Inpatient
    • 12.4.2. Outpatient
  • 12.5. Research Institutes
    • 12.5.1. Academic
    • 12.5.2. Private

13. Neurorehabilitation Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neurorehabilitation Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neurorehabilitation Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Neurorehabilitation Devices Market

17. China Neurorehabilitation Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. ANT Neuro B.V.
  • 18.7. Bioness, Inc.
  • 18.8. Bionik Laboratories Corp.
  • 18.9. BioXtreme Robotics Rehabilitation
  • 18.10. Boston Scientific Corporation
  • 18.11. BTS Bioengineering S.p.A.
  • 18.12. Cyberdyne Inc.
  • 18.13. Ekso Bionics Holdings, Inc.
  • 18.14. Hasomed GmbH
  • 18.15. Hocoma AG
  • 18.16. Kinetic Muscles, Inc.
  • 18.17. Kinova Inc.
  • 18.18. Medtronic plc
  • 18.19. MindMaze SA
  • 18.20. Myomo, Inc.
  • 18.21. NeuroStyle Pte Ltd
  • 18.22. ReWalk Robotics Ltd.
  • 18.23. Synertial Europe Ltd.
  • 18.24. Tyromotion GmbH
  • 18.25. Vibrant Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROREHABILITATION DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROREHABILITATION DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NEUROREHABILITATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NEUROREHABILITATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BRAIN COMPUTER INTERFACE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BRAIN COMPUTER INTERFACE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BRAIN COMPUTER INTERFACE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BRAIN COMPUTER INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ROBOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ROBOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ROBOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ROBOTICS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY END EFFECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY END EFFECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY END EFFECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TRANSCRANIAL DIRECT CURRENT STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TRANSCRANIAL DIRECT CURRENT STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TRANSCRANIAL DIRECT CURRENT STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TRANSCRANIAL DIRECT CURRENT STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ANODAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ANODAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ANODAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CATHODAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CATHODAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CATHODAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DTMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DTMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DTMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RTMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RTMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RTMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 18 TO 40, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 18 TO 40, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 18 TO 40, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 41 TO 64, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 41 TO 64, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 41 TO 64, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 65 PLUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 65 PLUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 65 PLUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 65 TO 74, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 65 TO 74, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 65 TO 74, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 75 TO 84, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 75 TO 84, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 75 TO 84, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 85 PLUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 85 PLUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY 85 PLUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CHILDHOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CHILDHOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CHILDHOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEONATAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ACADEMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ACADEMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ACADEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 250. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 251. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 253. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, 2018-2032 (USD MILLION)
  • TABLE 254. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, 2018-2032 (USD MILLION)
  • TABLE 255. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, 2018-2032 (USD MILLION)
  • TABLE 256. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 257. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY BRAIN COMPUTER INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 259. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY ROBOTICS, 2018-2032 (USD MILLION)
  • TABLE 260. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY TRANSCRANIAL DIRECT CURRENT STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 261. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 262. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY, 2018-2032 (USD MILLION)
  • TABLE 263. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 265. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 266. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 267. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, 2018-2032 (USD MILLION)
  • TABLE 269. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 270. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 271. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, 2018-2032 (USD MILLION)
  • TABLE 272. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 273. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 275. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 276. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 277. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, 2018-2032 (USD MILLION)
  • TABLE 278. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 282. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, 2018-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, 2018-2032 (USD MILLION)
  • TABLE 284. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, 2018-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 286. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY BRAIN COMPUTER INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 288. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY ROBOTICS, 2018-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY TRANSCRANIAL DIRECT CURRENT STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 290. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY, 2018-2032 (USD MILLION)
  • TABLE 292. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 294. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY GERIATRIC, 2018-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 296. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, 2018-2032 (USD MILLION)
  • TABLE 298. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 300. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL C